
News|Articles|March 1, 2008
FDA pipeline preview, March 2008
FDA-related information through March 2008 on C1 inhibitor, ferric carboxymaltose injection, lovastatin, carbidopa/levodopa extended release, vigabatrin, bortezomib, peginterferon alfa-2b, elesclomol, triphendiol, VQD-002
Advertisement
Complete response letter
Recommended for approval
Nonapprovable designations
Fast-track designations
Priority review
Orphan drug designations
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma
3
Centanafadine hits primary and key secondary endpoints in ADHD phase 3b trial
4
A conversation about vaccines and monoclonal antibodies with Marc Elia, Chairman of Invivyd’s Board of Directors
5
































